Vivimed Labs Limited

Vivimed Labs Limited: 7th Committee of Creditors Meeting Scheduled for Sep 10, 2026

Vivimed Labs Limited will hold its 7th Committee of Creditors meeting on September 10, 2026. The company is under Corporate Insolvency Resolution Process following an NCLT order. The meeting will be conducted via audio-visual means.

Vivimed Labs Limited Schedules 6th Committee of Creditors Meeting on August 18, 2026

Vivimed Labs Limited will hold its 6th Committee of Creditors meeting on August 18, 2026. This is a pre-facto intimation regarding the ongoing corporate insolvency resolution process.

Vivimed Labs Limited: No physical share transfer requests re-lodged in June 2026

Vivimed Labs Limited reported no activity regarding the re-lodgement of physical share transfer requests in June 2026. The company's Registrar and Share Transfer Agent confirmed zero requests received, processed, approved, or rejected during the month, as per SEBI guidelines.

Vivimed Labs Announces Newspaper Publication for Financial Results

Vivimed Labs Limited announced the publication of its financial results for the quarter and year ended March 31, 2026. The advertisements appeared in "Financial Express" and "Hosadigantha" on July 19, 2026, in compliance with SEBI regulations.

Vivimed Labs Limited Files SEBI Compliance Certificate for Q1 FY27

Vivimed Labs Limited submitted a certificate confirming compliance with SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended June 30, 2026. The RTA confirmed dematerialization actions were completed within the stipulated timeframe.

Vivimed Labs Limited Announces Trading Window Closure from July 1, 2026

Vivimed Labs Limited will close its trading window from July 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter ended June 30, 2026. The date of the board meeting for results declaration will be announced later.

Vivimed Labs Limited Initiates Corporate Insolvency Resolution Process

Vivimed Labs Limited has initiated its Corporate Insolvency Resolution Process (CIRP) with the publication of Form G. The company has manufacturing facilities across India and reported revenue from operations of ₹103.60 crore for FY 2025-26. The last date for expressions of interest is June 29, 2026.

Vivimed Labs Postpones Board Meeting for FY26 Financial Results

Vivimed Labs Limited's Board Meeting, scheduled for May 30, 2026, to approve FY26 financial results has been postponed. A revised date will be announced soon. The trading window remains closed for designated persons until 48 hours post-results declaration.

Vivimed Labs: Annual Secretarial Compliance Report for FY26

Vivimed Labs Limited filed its Annual Secretarial Compliance Report for the financial year ending 31 March 2026. The report, issued by Practicing Company Secretary N.V.S.S. Suryanarayana Rao on 30 April 2026, confirms compliance with SEBI regulations and good corporate practices.

Vivimed Labs Limited Enters Corporate Insolvency Resolution Process

Vivimed Labs Limited has entered Corporate Insolvency Resolution Process on April 15, 2026, as ordered by NCLT Bengaluru. Creditors must submit claims by May 1, 2026, to the IRP T Narayana Swamy. The estimated closure date for the process is October 11, 2026.

Vivimed Labs Admitted to Corporate Insolvency Resolution Process (CIRP)

Vivimed Labs Limited has been admitted to the Corporate Insolvency Resolution Process (CIRP) by the NCLT, Bengaluru, on April 15, 2026. The admission is due to an unpaid operational debt of ₹32.78 crore owed to Blue Cube Germany Assets GmbH & Co.KG. An Interim Resolution Professional has been appointed, and a moratorium has been declared.

Vivimed Labs Limited Files SEBI Compliance Certificate for Q4 FY26

Vivimed Labs Limited received a certificate from its RTA, Aarthi Consultants Private Limited, confirming compliance with SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended March 31, 2026. The RTA processed dematerialization requests within the stipulated 15-day period.

Vivimed Labs Limited Not Classified as Large Corporate Entity

Vivimed Labs Limited has declared that it is not classified as a 'large corporate entity' as per the SEBI framework. This announcement complies with SEBI Circular No. SEBI/HO/DDHS/CIR/P/2018/144.

Vivimed Labs Closes Trading Window from April 1, 2026, for Q4 FY26 Results

Vivimed Labs Limited will close its trading window from April 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and year ended March 31, 2026. The date for the board meeting to approve these results will be announced later.

Vivimed Labs Q3FY26 Unaudited Results: Net Loss Widens to ₹165.66 Crore

Vivimed Labs reported unaudited standalone results for Q3FY26 with revenue at ₹116.31 crore and a net loss of ₹165.66 crore. Consolidated revenue was ₹159.89 crore with a net loss of ₹97.50 crore. Auditors issued a qualified report citing unprovided interest, commission provisions, and ongoing forensic audit evaluations.

Vivimed Labs files for Pre-pack Insolvency Resolution Process with Rs. 512 Crore default

Vivimed Labs Limited filed an application for Pre-pack Insolvency Resolution Process on February 12, 2026. The company reported a default amount of ₹512.53 crore as of January 31, 2026. This action is taken under section 54A of the IBC Act.

Vivimed Labs Limited Secures Interim Stay on CBI Search and Seizure by High Court

Vivimed Labs Limited has received an interim stay from the Telangana High Court against CBI search and seizure operations initiated on January 20, 2026. The court has restrained coercive actions and actions based on SBI's 'fraud' classification of the company's account. The next hearing is scheduled for March 6, 2026.

Vivimed Labs CFO Phaninder Nath P S Resigns Due to Health Reasons Effective Feb 6, 2026

Mr. Phaninder Nath P S has resigned as Chief Financial Officer of Vivimed Labs Limited due to personal health issues. His resignation is effective February 06, 2026. He will also cease to be a Key Managerial Personnel.

Vivimed Labs Limited Receives Notice from CBI Regarding SBI Complaint

Vivimed Labs Limited received a notice from the CBI concerning a complaint by State Bank of India regarding financial irregularities. This follows Rare ARC's acquisition of the company's financial assets from SBI.

Vivimed Labs Limited: No Share Transfer Requests Processed in Special Window

Vivimed Labs Limited reported no physical share transfer requests received or processed during the special window period of December 1, 2025, to January 6, 2026. The company's Registrar and Share Transfer Agent confirmed NIL activity in approvals, rejections, and processing times.

Vivimed Labs Files SEBI Compliance Certificate for Q3 FY26

Vivimed Labs Limited filed a compliance certificate for the quarter ending December 31, 2025. The RTA confirmed adherence to SEBI regulations regarding securities dematerialization and record updates within the stipulated 15-day period.

Vivimed Labs Limited Clarifies Price Movement, Cites Market Conditions

Vivimed Labs Limited clarified to NSE that recent significant price movements in its shares are market-driven. The company confirmed no impending announcements that could impact the stock price, citing market conditions as the sole reason for the volatility.

Vivimed Labs: Trading Window Closed from Jan 1, 2026 for Q3 FY26 Results

Vivimed Labs Limited will close its trading window from January 1, 2026. The window will reopen 48 hours after the declaration of financial results for the quarter and nine months ended December 31, 2025. The date of the board meeting for results approval will be announced later.

Vivimed Labs Equity Trading Resumes Dec 18 After Suspension Revocation

Trading in Vivimed Labs Limited equity shares will resume on December 18, 2025, following the revocation of suspension by BSE and NSE. The company has complied with regulatory norms, including SEBI (LODR) Regulations, 2015.

Vivimed Labs EGM Approves Resolution for Insolvency Process

Vivimed Labs Limited held an EGM on December 10, 2025, to approve initiating a pre-packaged insolvency resolution process. The resolution was passed with 99.699% of the votes in favor. The e-voting period concluded on December 9, 2025.

Vivimed Labs EGM held on 10 Dec 2025

Vivimed Labs held an Extraordinary General Meeting (EGM) on December 10, 2025, to vote on the resolution for initiating pre-packaged insolvency resolution process.

Newspaper Publication Regarding EGM of Vivimed Labs Limited

Vivimed Labs Limited has published a newspaper advertisement regarding the Extraordinary General Meeting (EGM) of the Company.

Vivimed Labs announces EGM publication in newspapers

Vivimed Labs announces newspaper publication for EGM to be held via video conferencing, with notice dispatched electronically. Advertisements published on November 16, 2025.

Vivimed Labs to hold EGM on Dec 10, 2025, to approve pre-packaged insolvency resolution process

Vivimed Labs will hold an EGM on December 10, 2025, to approve initiating a pre-packaged insolvency resolution process due to debt challenges. E-voting from Dec 07-09.

Vivimed Labs publishes financial results for Q2 and H1 ended September 30, 2025 in newspapers

Vivimed Labs Limited published its financial results for the quarter and half-year ended September 30, 2025, in "Financial Express" and "Hosadigantha" on November 15, 2025.

Vivimed Labs Approves Unaudited Financial Results, EGM Notice, and Application to NCLT

Vivimed Labs approves unaudited financial results for Q2 FY26, plans EGM for NCLT application, and expects trading suspension revocation. The company did not provide for interest expenses of ₹157.28 million for the quarter.

Vivimed Labs reports Q2 losses, files for pre-packaged insolvency, expects trading suspension revocation

Vivimed Labs reported Q2 losses, approved filing for pre-packaged insolvency, and expects trading suspension revocation. Auditors issued a qualified opinion due to unprovided interest expenses.

Vivimed Labs Board Approves Q2 Results, Pre-packaged Insolvency Application, and Trading Suspension Revocation Expected

Vivimed Labs reported significant losses for Q2 FY26 with a qualified audit opinion due to unrecorded interest. The board approved applying for pre-packaged insolvency and expects trading suspension revocation.

Intimation for Re-Lodgement of Physical Share Transfer Requests

Vivimed Labs received a report on re-lodgement of physical share transfer requests as per SEBI guidelines. No requests were processed during October 2025.

Vivimed Labs' SBI Debt Assigned to Rare Asset Reconstruction Ltd.

Vivimed Labs' debt from State Bank of India has been assigned to Rare Asset Reconstruction Ltd., transferring all recovery rights and obligations to the ARC, indicating a significant change in creditor.

Vivimed Labs confirms compliance with SEBI (Depositories and Participants) Regulations for Q2 FY26

Vivimed Labs confirmed compliance with SEBI (Depositories and Participants) Regulations 74(5) for the quarter ended 30th September, 2025, as certified by its RTA, Aarthi Consultants Private Limited.

Vivimed Labs receives RTA report on physical share transfer re-lodgement requests

Vivimed Labs received a report from its RTA on re-lodgement requests for physical shares, as per SEBI circular. The report showed NIL requests received or processed as of September 2025.

Proceedings of 37th Annual General Meeting

Report on Re-lodgement of Physical Share Transfer Requests

Newspaper Publication for 37th AGM

Vivimed Labs to Hold 37th AGM, Proposes ₹500 Crore Fundraise and Key Director Re-appointments